Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ORIC | Common Stock | Options Exercise | $0 | +14K | +93.31% | $0.00 | 29.1K | Dec 15, 2023 | Direct | F1, F2 |
transaction | ORIC | Common Stock | Sale | -$45.4K | -5.28K | -18.16% | $8.59 | 23.8K | Dec 15, 2023 | Direct | F3, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ORIC | Restricted Stock Unit | Options Exercise | $0 | -6.04K | -50% | $0.00 | 6.04K | Dec 15, 2023 | Common Stock | 6.04K | Direct | F1, F5 | |
transaction | ORIC | Restricted Stock Unit | Options Exercise | $0 | -8K | -33.33% | $0.00 | 16K | Dec 15, 2023 | Common Stock | 8K | Direct | F1, F6 |
Id | Content |
---|---|
F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock. |
F2 | Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan. |
F3 | Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person. |
F4 | Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.795 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
F5 | 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. |
F6 | 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025. |